Why is a vaccine against B. melitensis important?
George Tice, Senior Director of Market Access for Europe, Middle East and Africa at Elanco Animal Health responds with his personal view.
GALVmed and AgResults announced the launch of the Brucellosis Vaccine Initiative, a US $30 million prize competition aimed at incentivising animal health companies to develop a vaccine against brucellosis to be used mainly in developing countries.
The prize – one of the largest of its kind – is funded by AgResults, a collaborative initiative between the governments of Australia, Canada, the UK and the US as well as the Bill & Melinda Gates Foundation in an effort to find innovative solutions from the private sector to seemingly intractable development challenges. GALVmed will act as the pilot manager and manage the implementation of the prize over the nearly ten year prize competition.
The initiative was launched at the IFAH-Europe Conference on 16 June 2016.
Contact GALVmed’s Brucellosis team at firstname.lastname@example.org.